FDA approves Welireg and Lenvima combination for advanced renal cell carcinoma. Learn about this breakthrough treatment for ...
BigHat Biosciences secures $75M Series C to advance AI-designed protein therapeutics. Total funding reaches $223M. Discover ...
XtalPi files FDA IND application for KQTD-126, a gut-restricted pan-TRK inhibitor for chronic intestinal pain. First-in-class ...
Addex Therapeutics regains full global rights to GABAB PAM portfolio from Indivior. Collaboration termination follows ...
Earendil Labs partners with Genentech for AI-designed bispecific antibodies in oncology. $1.5B+ deal includes $55M upfront payment and milestone targets.
Siemens Healthineers and Novo collaborate to expand non-invasive blood-based testing for MASLD and MASH. Learn about this healthcare partnership.
Celldex reports positive Phase 3 results for barzolvolimab in chronic urticaria, meeting primary endpoints. Read the ...
Otsuka's ulefnersen becomes first drug to meet primary endpoint in placebo-controlled FUS-ALS trial, targeting rare genetic ...
FDA approves Elevar's Lyrfigtu (lirafugratinib) for previously treated cholangiocarcinoma with FGFR2 fusion. Learn about this breakthrough cancer treatment.
Astellas doses first patient in Phase III setidegrasib trial for KRAS G12D lung cancer. First-in-class treatment with no approved competitors. Read more.
Eli Lilly partners with Beijing-based InnoCare Pharma in $3.25B strategic collaboration for oncology and autoimmune disease ...
Arcturus Therapeutics unveils LUNAR 2.0 platform with 38-fold potency increase for OTC deficiency treatment. Phase II interim data released. Read more.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results